Analysts Offer Predictions for CalciMedica Q4 Earnings

CalciMedica, Inc. (NASDAQ:CALC) – Research analysts at HC Wainwright issued their Q4 2025 earnings estimates for CalciMedica in a research note issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.48) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share.

CalciMedica Stock Down 5.1 %

CALC opened at $1.85 on Wednesday. The firm has a market cap of $24.94 million, a P/E ratio of -1.71 and a beta of 1.20. The business’s fifty day simple moving average is $2.32 and its 200 day simple moving average is $3.11. CalciMedica has a 52 week low of $1.81 and a 52 week high of $6.27.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Thursday, March 27th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14.

Institutional Investors Weigh In On CalciMedica

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares during the last quarter. PVG Asset Management Corp purchased a new position in shares of CalciMedica during the 3rd quarter worth $67,000. Atria Investments Inc boosted its holdings in shares of CalciMedica by 28.3% during the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock worth $120,000 after purchasing an additional 7,509 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of CalciMedica in the fourth quarter valued at $135,000. Finally, Renaissance Technologies LLC acquired a new position in CalciMedica in the fourth quarter valued at $153,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.